Vaccines for Cancer

Mary Lenora Disis; Brie M. N. Chun; Kiranjit K. Dhillon; John B. Liao; Natasha B. Hunter; Denise L. Cecil

doi:10.1001/jama.2026.15540

Medicina y saludTratamiento del cáncer

Vaccines for Cancer

Mary Lenora Disis, Brie M. N. Chun, Kiranjit K. Dhillon, John B. Liao, Natasha B. Hunter, Denise L. Cecil

Revista con revisión por paresUso en el mundo real

En palabras de los autores

Esta revista no permite republicar el resumen completo. Estas son las dos oraciones que eligió Pipette, citadas textualmente. El resto está en el sitio de la editorial.

Resultado principal

Conclusions and Relevance: Cancer vaccines can treat several types of malignant neoplasms, including melanoma, prostate cancer, and bladder cancer.

Leer el paper

Apareció: miércoles, 23 de septiembre. JAMA. Revista con revisión por pares.

DOI: 10.1001/jama.2026.15540

Medicina y salud Tratamiento del cáncer 23 de sept de 2026
Intense TP53 pathway selection drives clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease
Our findings establish ED as a paradigm of preleukemic dependency on p53-pathway attenuation.
S. Douglas, I. Kaaja, I. Ikonen y 13 más — medRxiv
Preprint
Medicina y salud Tratamiento del cáncer 23 de sept de 2026
Targeting Polθ Helicase with RP-3467: Preclinical Validation and Clinical Response in a gBRCA1 ovarian cancer patient with an acquired PARPi resistance mutation in TP53BP1
A heavily pretreated germline BRCA1-mutant ovarian cancer patient achieved a confirmed partial response to RP-3467 plus olaparib (RECIST v1.1), with retrospective profiling revealing a TP53BP1 loss-of-function mutation previously linked to both PARPi resistance and POLQ dependency.
A. Sfeir, E. Rosen, M.-C. Mathieu y 29 más — medRxiv
PreprintUso en el mundo real
Medicina y salud Tratamiento del cáncer 23 de sept de 2026
Geographic and clinical predictors of one-day discharge after radical prostatectomy: a SEER-Medicare cohort study
ConclusionsOne-day discharge after radical prostatectomy has increased over time and is now the predominant practice among Medicare beneficiaries, driven primarily by robotic surgery and treatment era.
J. Hanna, M. R. Shanahan, J. Sykes y 3 más — medRxiv
PreprintUso en el mundo real
Medicina y salud Tratamiento del cáncer 23 de sept de 2026
Cost-Effectiveness of Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Adenocarcinoma
ResultsIn the RAS G12 population, daraxonrasib generated 0.652 additional life-years and 0.506 additional QALYs at an incremental cost of $253, 171, y i e l d in g an I C E R o f$ 500,637/QALY.
S. Han, N. Starasvetskaya, G. Terrero y 2 más — medRxiv
PreprintUso en el mundo real
Medicina y salud Tratamiento del cáncer 23 de sept de 2026
Genomic foundation models extend clinicopathologic and transcriptomic prognostication in soft tissue sarcoma
ConclusionsEvo2-derived genomic representations improved clinicopathologic and transcriptomic prognostication across sarcoma cohorts and survival endpoints.
M. Esperanca-Martins, M. Sokolov Ravasqueira, S. Dias y 3 más — medRxiv
Preprint

Todos los papers nuevos de Tratamiento del cáncer

Vaccines for Cancer

En palabras de los autores

Más de Tratamiento del cáncer ese día

Intense TP53 pathway selection drives clonal evolution from bone marrow failure to leukemia in ERCC6L2 disease

Targeting Polθ Helicase with RP-3467: Preclinical Validation and Clinical Response in a gBRCA1 ovarian cancer patient with an acquired PARPi resistance mutation in TP53BP1

Geographic and clinical predictors of one-day discharge after radical prostatectomy: a SEER-Medicare cohort study

Cost-Effectiveness of Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Adenocarcinoma

Genomic foundation models extend clinicopathologic and transcriptomic prognostication in soft tissue sarcoma